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Abstract
Objective
To characterize the clinical and neuropathologic features of patients with amyotrophic lateral
sclerosis (ALS) with the superoxide dismutase 1 (SOD1) p.Ala90Val mutation, as well as the
mutation frequency and the role of oligogenic mechanisms in disease penetrance.
Methods
An index patient with autopsy-proven ALS was discovered to have the SOD1 p.Ala90Val
mutation, which was screened in 2 Finnish ALS cohorts (n = 453). Additional contributing
variants were analyzed from whole-genome or whole-exome sequencing data.
Results
Seven screened patients (1.5%) were found to carry the SOD1 heterozygous mutation. Allele-
sharing analysis suggested a common founder haplotype. Common clinical features included
limb-onset, long disease course, and sensory symptoms. No TDP43 pathology was observed.
All cases were apparently sporadic, and pedigree analysis demonstrated that the mutation has
reduced penetrance. Analysis of other contributing genes revealed a unique set of additional
variants in each patient. These included previously described rare ANG and SPG11 mutations.
One patient was compound heterozygous for SOD1 p.Ala90Val and p.Asp91Ala.
Conclusions
Our data suggest that the penetrance of SOD1 p.Ala90Val is modulated by other genes and
indicates highly individual oligogenic basis of apparently sporadic ALS. Additional genetic
variants likely contributing to disease penetrance were very heterogeneous, even among
Finnish patients carrying the SOD1 founder mutation.
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Superoxide dismutase 1 (SOD1) mutations are the second
most common cause of familial amyotrophic lateral sclerosis
(ALS) explaining approximately 12%–20% of familial and
1%–2% of sporadic ALS.1 Usually, SOD1 mutations have an
autosomal dominant pattern of inheritance.1
SOD1 mutation c.269C>T, p.Ala90Val (previously called
A89V) has been described in 3 family members with ALS with
variable age at onset, incomplete penetrance, and sensory
neuropathy2 and in 4 additional individuals with ALS.3–5 The
ethnicity of the patients was not reported.
We identiﬁed the SOD1 p.Ala90Val mutation through whole-
exome sequencing (WES) in our neuropathologically exam-
ined index patient with ALS and investigated its frequency
and additional genetic burden in 2 Finnish ALS cohorts.
Methods
The index patient was autopsied because of a clinically atyp-
ical motor neuron disease. DNA was extracted from his liver
tissue, and a heterozygous SOD1 p.Ala90Val mutation was
found in WES performed at the Institute for Molecular
Medicine Finland (FIMM, Helsinki, Finland). This mutation
was screened in 2 ALS cohorts. The Helsinki cohort (n =
300), collected 1995–2014, was subjected to whole-genome
sequencing (WGS) at Broad Institute, Boston, MA. The
Turku cohort (n = 153) consisted of samples sent to the
TYKS Laboratory of Medical Genetics between 2007 and
2016 for SOD1 sequencing with the diagnosis of deﬁnitive or
probable ALS or phenotype consistent with motor neuron
disease in the referral. WES was performed at FIMM to the
p.Ala90Val mutation–positive samples of the Turku cohort.
Sequencing details are shown in e-Methods. All p.Ala90Val-
positive samples were screened for the C9orf72 repeat ex-
pansion using the previously described method.6
To identify additional coding or splicing variants in the
p.Ala90Val-positive samples, we analyzed other neurodegener-
ative disease and SOD1 pathway genes from their WES/WGS
data (e-methods and table e-1, links.lww.com/NXG/A152).
Neuropathologic analysis was performed following the stan-
dard protocol. Clinical information was examined from
medical records.
Standard protocol approvals, registrations,
and patient consents
This study was approved by the local ethics committees. In-
formed consent was given by the patients/relatives, or the
approval for the use of patient tissue samples was obtained
from the National Supervisory Authority for Welfare and
Health (Valvira).
Data availability statement
The data set is available upon reasonable request from the
corresponding author.
Results
Genetic analyses
The SOD1 mutation NM_000454.4 c.269C>T, p.Ala90Val
found in the index patient was analyzed in the Helsinki and
Turku cohorts (n = 453). Seven additional heterozygous cases
were found (1.5%). This mutation is in the gnomAD data-
base7 in 1/8,367 Finnish samples (heterozygote) but absent
in all other populations (95,693 samples) after removing
neurologic patients. There is a statistically signiﬁcant diﬀer-
ence in the carrier frequency of the p.Ala90Val between the
Finnish patients with ALS (7/453, excluding index) and the
Finnish gnomAD population (1/8,367) (p = 6.9 × 10−9,
Fisher exact test).
Although the patients were not known to be related, allele-
sharing analysis of the samples indicates a common haplotype
of at least 379,7 kb (Chr21:32723906-33103636) with 8 rare
single nucleotide polymorphismmarkers, implying a common
ancestor (table e-2, links.lww.com/NXG/A152).
None of the patients had a family history of ALS, and alto-
gether 6 unaﬀected carriers (aged 50–87 years) of p.Ala90Val
were identiﬁed in the families of P6 and P8 (ﬁgure e-1, links.
lww.com/NXG/A152). Analysis of other neurodegeneration
implicated genes (n = 1,115) revealed that all patients had
additional potentially contributing variants (table and table
e-3, links.lww.com/NXG/A152). Each patient had a unique
proﬁle of other variants, the number of possibly or probably
contributing variants varied between 4 and 14 per patient.
Seven of the 8 patients had at least 1 variant that we consid-
ered “probably pathogenic” (table and table e-3, links.lww.
com/NXG/A152). Three patients had mutations previously
described in ALS: P6, a heterozygous ANG mutation; P7,
a heterozygous SPG11 mutation; and P8 was compound
heterozygous for SOD1 p.Ala90Val and p.Asp91Ala con-
ﬁrmed by family member testing (ﬁgure e-1, links.lww.com/
NXG/A152). Four other patients had probably pathogenic
variants in genes previously associated with motor neuron
disease or peripheral neuropathy: P1 in ARHGEF28, P3 in
UNC13A, P4 in ARHGEF10, and P5 in ADGRB2/BAI2. P2
was the only one who did not have any probably pathogenic
Glossary
ALS = amyotrophic lateral sclerosis; IHC = immunohistochemistry; SOD1 = superoxide dismutase 1; WES = whole-exome
sequencing; WGS = whole-genome sequencing.
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Table Clinical features and selected genetic findings of patients 1–8
Patient
P1 P2 P3 P4 P5 P6 P7 P8
Male Female Female Male Female Female Male Female
Age at onset
(y)
40 51 70 47 43 32 48 50
Disease
duration (y)
14 7 7 18 25a 6a 15a 7
Site of onset Lower limb Limbb Upper limb Lower limb Lower limb Lower limb Lower limb Lower limb
Initial
symptoms
Cramps,
difficulties with
balance, and
diminished
control of legs
NA Weakness of
limbs,
predominantly
right upper
limb
Difficulty
walking,
stumbling,
and
problems
with balance
Muscle
twitches
Distal lower
limb
weakness
Pain and later
weakness in the
lower limbs
Distal lower
limb
weakness
Sensory
symptoms
Yes NA No Yes Yes No Yes No
Initial EMG Sensorimotor
polyneuropathy
NA Motor axon
damage,
suggestive of
motor neuron
disease
Consistent
with motor
neuron
disease
Consistent
with motor
neuron
disease
Compatible
with motor
neuron
disease
Compatible with
motor neuron
disease
Compatible
with motor
neuron
disease
Sensory
neuropathy
in EMG
Yesc NA No Yesc No No No No
Cognitive
symptoms
No NA Yesd No No No No No
Cerebral
infarct in
MRI
No NA Yesd Yes No NA NA NA
Creatine
kinase
Elevated NA Normal Elevated Slightly
elevated
Normal Normal
Cause of
death
ALS Suspected
myocardial
infarction
ALS Respiratory
failure
a a a ALS
Family
history of
ALS
No NA No No No No No No
C9orf72 Normal Normal Normal Normal Normal Intermediate
allele (23
repeats)
Normal Normal
Probably
pathogenic
variants in
WES/WGS/
other tests
WES: ARHGEF28:
p.T248R
WGSe WGS: UNC13A:
p.R298W
WGS:
ARHGEF10:
p.P234T
WGS:
ADGRB2/
BAI2p.S63L
WES: ANG:
p.K78Ef
WES: SPG11:
p.Q1875X
CACNA1H:
p.R1231C
homozygous
SMN2 deletiong
WES:
1.SOD1:
p.D91Af
Abbreviations: ALS = amyotrophic lateral sclerosis; NA: information not available; WES = whole-exome sequencing; WGS = whole-genome sequencing.
a The patient is alive.
b More detailed information about the site of onset is not available.
c The amplitude of antidromic sensory potentials of patient P1 at age 40 years: median nerve 4.8mV (normal value ³20mV), ulnar nerve 3.6mv (normal value
³17mV), and sural nerve 5.8mV (normal value ³6mV), and of patient P4 at age 53 years: ulnar nerve 4.9mV and sural nerve 8.7 mV; themedian nerve had no
response in the study. The EMG studies were performed using the standard protocol.
d In addition to small old infarcts in the left occipital lobe and right posterior frontal area, there was a mild expansion in the cortical liquor spaces and mild
atrophy in the hippocampi, changes in the pons area and in the periventricular white matter that were interpreted as degenerative. This patient also had
cognitive symptoms, and a neuropsychological assessment at age 76 years revealed predominantly frontal lobe problems that were not at the level of
dementia.
e The patient had variants in 3 SOD1 pathway genes: FBXW8, NOB1, and ALOX15.
f Mutation has been previously reported in patients with ALS; the references are in the supplemental material (e-references, links.lww.com/NXG/A152).
g Deletions in exons 7 and 8 of the SMN1 and SMN2 genes were investigated by the PCR-restriction fragment length polymorphismmethod. Comprehensive
list and information of genetic variants are in table e-3, links.lww.com/NXG/A152.
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variants according to our interpretation; she had nevertheless
variants in 3 SOD1 pathway genes: FBXW8, NOB1, and
ALOX15 (table e-3, links.lww.com/NXG/A152). None of the
patients had a C9orf72 repeat expansion, but P6 had 23 hex-
anucleotide repeats in C9orf72 (the signiﬁcance of which is
presently unclear).
Clinical features
The patients’ clinical features are summarized in the table.
The age at onset was variable (32–70 years). All had a limb-
onset disease, with typical presenting symptoms including
fasciculations, weakness, and diﬃculties with walking and
balance. The initial EMG and nerve conduction study of P1
(index) revealed sensorimotor polyneuropathy; later, he had
stocking-like sensory abnormalities in both feet, and both
soles showed hyperesthesia in addition to the motor symp-
toms. The initial EMG of P4 was consistent with motor
neuron disease, and a later EMG revealed additional distal
sensory polyneuropathy. P7 had reduced vibration sense in
his feet, and P5 had paresthesia in her hands. All patients had
a long disease course, 7–25+ years; 3 of the patients were still
alive at the time of this study.
Neuropathologic features
The index patient’s brain weighed 1527 g and appeared
macroscopically normal. The anterior roots of the spinal cord
were atrophic. Microscopically, the anterior horns showed
signiﬁcant loss of neurons (ﬁgure, C).
The axon density was markedly lowered in the anterior roots
compared with the dorsal roots (ﬁgure, A–B).
There was mild neurodegeneration in the hypoglossal nucleus
at the level of the medulla oblongata (ﬁgure, D). Immunohis-
tochemistry (IHC) showed no TDP43-positive inclusions in
the anterior horns, cortical areas, or in the hypoglossal nucleus.
No hyaline conglomerate inclusions, reported to be speciﬁc for
some SOD1 mutations,8 were detected on neuroﬁlament
(SMI32) IHC. Tau, and beta amyloid stainings were negative.
P62 staining showed only a few positive neurites, but no
intraneuronal inclusions. The muscle samples showed very
strong group atrophy and fairly abundant reinnervation
(ﬁgure, E–F). The cause of death was concluded to be motor
neuron disease.
Figure Neuropathologic findings of the autopsied patient (index)
(A) Plastic-embedded sections from the dorsal spinal
root show normal density of axons, whereas (B) se-
vere loss of bothmyelinated and unmyelinated axons
is seen in the anterior spinal roots (toluidine blue
×600magnification). (C) There is severe neuronal loss
in the anterior spinal columns, and the remaining
neurons appear chromatolytic (hematoxylin and eo-
sin [HE]-stained section from the lumbar spinal cord,
×400magnification). (D) The hypoglossal nucleus was
mildly degenerated (HE-stained section from the
medulla oblongata, ×400 magnification. (E) Muscle
biopsy taken from the vastus lateralis showed atro-
phic small groups (arrow) and overrepresentation of
type 2 fibers, suggesting abundant reinnervation
(double immunohistochemistry for myosin, ×200
magnification). (F) Higher magnification shows that
both type 1 (brown) and type 2 (red) fibers (arrows)
are atrophic (×400 magnification).
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Discussion
In this study, 1.5% of the patients with ALS carried the SOD1
mutation p.Ala90Val, making it a major mutation in Finnish
patients with ALS based on its frequency, although it had
previously been described in only 7 patients.2–5 In the Hel-
sinki cohort, it is the third most common currently known
ALS mutation after C9orf72 repeat expansion and SOD1
p.Asp91Ala (unpublished data). There is a clear enrichment
of p.Ala90Val in the Finnish population.
There were 6 unaﬀected family members who were conﬁrmed
to carry the p.Ala90Val mutation illustrating the proposed
reduced penetrance and oligogenic mechanisms in ALS.4 The
SOD1 p.Ala90Val probably plays a dominating role in our
patients despite the additional rare variant burden because (1)
the clinical features were similar in all patients thus far
reported2 and (2) the neuropathology of the index patient
was consistent with SOD1-related ALS.9 The p.Ala90Val
mutation has been shown to cause a conformational change
on the SOD1 protein,10 and SOD1 enzymatic activity has
been shown to be reduced in the CSF of a patient with the
mutation.5 In silico analysis with MutationTaster (muta-
tiontaster.org/), PolyPhen-2 (genetics.bwh.harvard.edu/
pph2/), and SIFT (provean.jcvi.org/index.php) predicts p.
Ala90Val to be deleterious.
We cannot exclude the role of environmental factors in disease
penetrance with total conﬁdence. However, 3 of the 8 patients
had mutations previously described in ALS, and 4 additional
patients had probably pathogenic rare variants in genes pre-
viously implicated in motor neuron disease or peripheral
neuropathy. Our data represent an illustrative example of
a mutation whose penetrance appears to require additional
genetic factors. It also demonstrates the genetic heterogeneity
of sporadic ALS: despite sharing a founder mutation, the
spectrum of other variants was very heterogeneous; each pa-
tient had a unique set of variants. The small sample size and
varying sequencingmethodology preclude powerful analyses of
the discovered variants on clinical features. At present, it is not
possible tomake ﬁrm conclusions on the pathogenic role of the
potentially contributing variants in individual patients, although
in the p.Asp91Ala compound heterozygous P8, the disease-
causing eﬀect is clear. The allele frequency of many variants
(table e-3, links.lww.com/NXG/A152) suggests predisposing
or disease-modifying rather than disease-causing eﬀects.
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